$1.58
0.031.94%
Últ. Act.: Oct 2, 7:15 AM
$1.61
0.063.87%
RenovoRx (RNXT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
RenovoRx (RNXT) publicó su última previsión de agosto 12, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $3.75M - $4.25M para el período.
En comparación con la previsión anterior, RenovoRx elevado redujo su previsión de ingresos desde un rango anterior de $3M - $4M.
RenovoRx ha emitido 2 actualizaciones de orientación entre el mayo 14, 2026 y el agosto 12, 2026. During this period, the company raised its outlook 1 time, reflecting management's growing confidence in business performance.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.08 | $-0.08 | $-0.08 | $-0.08 |
| Actual | $-0.05 | $-0.08 | $-0.08 | $-0.08 |
| Surprise | +37.5% | 0.00% | 0.00% | 0.00% |
| Revenue | ||||
| Estimate | $709000 | $470600 | $451850 | $346400 |
| Actual | $909000 | $563000 | $238000 | $266000 |
| Surprise | +28.2% | +19.6% | -47.3% | -23.2% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.05 | $-0.05 | $-0.05 | $-0.04 |
| Revenue | ||||
| Consensus | $1.1M | $1.3M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $-0.05 | $-0.08 | 37.5 % |
| Q1 | May 14, 2026 | $-0.08 | $-0.08 | 0.00 % |
| Q4 | Mar 30, 2026 | $-0.08 | $-0.08 | 0.00 % |
| Q3 | Nov 13, 2025 | $-0.08 | $-0.08 | 0.00 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $909.00K | $709.00K | 28.2 % |
| Q1 | May 14, 2026 | $563.00K | $470.60K | 19.6 % |
| Q4 | Mar 30, 2026 | $238.00K | $451.85K | -47.3 % |
| Q3 | Nov 13, 2025 | $266.00K | $346.40K | -23.2 % |